61 results found

It can be hard to choose the most appropriate and cost-effective means of protecting designs within the European Union.

A decision (T1780/12) from the EPO technical boards of appeal indicates that Swiss-type claims of the form "Use of [product X] in the manufacture of a medicament for the treatment of [disease Y]" provide a different scope of protection than EPC 2000 second medical use claims of the form "[product X] for use in the treatment of [disease Y]".

The UK’s High Court has decided that Genentech’s patent relating to a composition of Herceptin with reduced acidic variant content is invalid.

The Patent Prosecution Highway (PPH) offers a system through which patent prosecution can be accelerated in one participating jurisdiction provided the claims of interest have been found to be acceptable in another participating jurisdiction

The UK’s High Court recently decided upon Dr Reddy’s application to revoke the 6 month paediatric extension of Warner-Lambert’s SPC for atorvastatin (Lipitor), which is used for lowering blood cholesterol.

The EPO central limitation procedure has shown its potential to disrupt infringement and validity hearings in the UK courts, after the Court of Appeal agreed to adjourn an appeal in the ongoing dispute between Apple and Samsung.

A recent judgment of the UK Court of Appeal in HTC v Apple considered whether computer implemented methods utilised in touchscreen devices were excluded from patentability.

A recent decision from the UK Court of Appeal in Adaptive Spectrum and Signal Alignment Inc. v British Telecommunications Plc. has shown that the UK courts are prepared to impose injunctions on big telecoms operators, but that in doing so consideration may well be given to the effect an injunction will have on the public.

Mr Justice Arnold in the Patents Court of the High Court of England and Wales (the ‘Patents Court’) initially refused a request by the patentee, Pharmacia, for a stay of UK revocation proceedings brought by Actavis, pending the outcome of opposition proceedings at the EPO based on three undertakings.

New legislation drafted by the UK government should shield clinical trials in the UK from the risk of patent infringement in the near future.

The High Court decided that Smith & Nephew’s DURAFIBER Ag™ wound care product does not infringe ConvaTec’s patent relating to silverised wound dressings, and refused to grant springboard relief to ConvaTec based on infringing experiments carried out by Smith & Nephew to obtain regulatory approval for their product.

Recent innovations in women's health technology are empowering women to monitor their wellbeing, manage symptoms, and close the gender health gap through wearables, neurostimulation devices, and at-home testing solutions. As FemTech products combine physical devices, digital platforms, and healthcare functions, innovators face unique challenges in protecting their intellectual property across multiple jurisdictions.

The IP Bill recently received Royal Assent and became the IP Act 2014 ("the Act"). This article summarises the most significant changes to UK law relating to both patents and designs brought about by provisions in the Act that will start to come into force from 1st October 2014.

The recent judgment in Schütz v Werit from the Supreme Court (the UK’s highest court) has provided guidance on the question of when repairing a patented product by replacing a component part infringes a patent to the product as a whole.

Following widespread litigation over Halozyme's SPC families for Herceptin Hylecta and MabThera, Europe's highest court received a critical referral addressing whether recombinant human hyaluronidase can be considered an "active ingredient" despite its classification as an excipient in marketing authorisation documents. Advocate General Emiliou has now published a significant legal opinion proposing that substances expressly designated as excipients cannot be regarded as active ingredients for SPC purposes.

In AstraZeneca v KRKA, d.d. Novo Mesto and Consilient Health Ltd. ("KRKA"), the Mr Justice Sales of the UK High Court has considered the merits of arguments put forward when trying to recover damages following a cross-undertaking in respect of an interim injunction that was subsequently discharged.

The UK IPO’s updated guidance should reduce Section 1(2) objections, but applicants may still face difficult questions about which claim features make a technical contribution...

How can intellectual property rights protect innovations designed specifically for women and underrepresented groups in product safety? This article explores the intersection of inclusive design and IP strategy, examining patents, design rights, and trade marks as tools for safeguarding innovations that address long-overlooked safety gaps in consumer products.